<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688320</url>
  </required_header>
  <id_info>
    <org_study_id>FORPE</org_study_id>
    <nct_id>NCT04688320</nct_id>
  </id_info>
  <brief_title>Recombinant Non-immunogenic Staphylokinase VS Alteplase for Massive PE a Randomized Non-inferiority Trial</brief_title>
  <official_title>Multicenter, Open Label, Randomized Comparative Trial of the Efficacy and Safety of a Single Bolus Recombinant Non-immunogenic Staphylokinase and Bolus-infusion of Alteplase in Patients With Massive Pulmonary Embolism (FORPE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supergene, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supergene, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: to evaluate the efficacy and safety of the Recombinant Non-immunogenic&#xD;
      Staphylokinase with its single bolus administration in comparison with the bolus-infusion&#xD;
      administration of the Alteplase in patients with massive pulmonary embolism&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main goal of treating massive PE is to save the lives of patients by restoring pulmonary&#xD;
      perfusion, preventing the development of chronic postembolic pulmonary hypertension and&#xD;
      recurrent PE. According to data of clinical trials, with timely initiation of therapy for&#xD;
      massive pulmonary embolism, mortality can be significantly reduced.&#xD;
&#xD;
      Recombinant protein which contains aminoacid sequence of staphylokinase - Fortelizin® (the&#xD;
      active substance is Forteplase). It is single chain molecula, consists of 138 aminoacids,&#xD;
      weight 15.5 kDa. When staphylokinase is added to human plasma containing a fibrin clot, it&#xD;
      preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase&#xD;
      complex. This complex activates plasminogen trapped in the thrombus. The&#xD;
      plasmin-staphylokinase complex and plasmin bound to fibrin are protected from inhibition by&#xD;
      alpha2-antiplasmin. Once liberated from the clot (or generated in plasma), however, they are&#xD;
      rapidly inhibited by alpha2-antiplasmin. This selectivity of action confines the process of&#xD;
      plasminogen activation to the thrombus, preventing excessive plasmin generation,&#xD;
      alpha2-antiplasmin depletion, and fibrinogen degradation in plasma. In rabbits anti&#xD;
      forteplase antibodies are not produced. It was achieved by replacement of amino acids in&#xD;
      immunogenic epitop of molecule staphylokinase. Blood fibrinogen decrease after i.v. injection&#xD;
      of Fortelyzin less 10% within first 24 hours. Angiographic data suggests that restoration of&#xD;
      coronary blood flow appears in up to 80% of patients with STEMI after i.v. injection of&#xD;
      Fortelyzin.&#xD;
&#xD;
      The main objectives of the study:to assess the efficacy , safety and possible adverse events&#xD;
      of the drug Recombinant Non-immunogenic Staphylokinase with its single bolus administration&#xD;
      in comparison with the bolus-infusion administration of the drug Alteplase® in patients with&#xD;
      massive pulmonary embolism.&#xD;
&#xD;
      Study Design. Multicenter, open-label, randomized, comparative clinical study of&#xD;
      non-inferiority study of efficacy and safety in parallel groups. At clinical centers,&#xD;
      patients will be equally randomly distributed by the &quot;envelope&quot; method into two groups of 155&#xD;
      patients each (310 people in total, including 10% of those who may have dropped out)to&#xD;
      receive Recombinant Non-immunogenic Staphylokinase or Alteplase®.&#xD;
&#xD;
      The drugs will be administered after the signed informed consent. Recombinant Non-immunogenic&#xD;
      Staphylokinase will be administered intravenously at a dose of 15 mg as a single bolus for&#xD;
      10-15 seconds. Alteplase® will be administered in accordance with the instructions for use.&#xD;
&#xD;
      Patients will be monitored for 30 days from the moment of randomization: in the intensive&#xD;
      care unit up to 7 days, after it in the hospital until discharge - an average of 14 days and&#xD;
      an outpatient visits on the 30th day. The recruitment of patients for the study will be&#xD;
      competitive.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>At clinical centers, patients will be equally randomly distributed by the &quot;envelope method&quot; into two groups to receive Fortelizin® or Alteplase®.&#xD;
The drugs will be administered after the signed informed consent. Fortelizin® will be administered intravenously at a dose of 15 mg as a single bolus for 10-15 seconds. Alteplase® will be administered in accordance with the instructions for use. All patients will be examination for 30 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All eligible patients will be randomized in two equal groups for administration recombinant nonimmunogenic staphylokinase (Fortelyzin) or alteplase (Actilize) by using &quot;envelope method&quot; of randomization.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy endpoint</measure>
    <time_frame>within 7 days</time_frame>
    <description>death from all causes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Massive Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Recombinant nonimmunogenic staphylokinase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lyophilisate for preparation of a solution for intravenous administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, intravenously as a quick single bolus injection for 10-15 seconds, regardless of body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alteplase® is administered in accordance with the instructions for use for pulmonary embolism( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant nonimmunogenic staphylokinase</intervention_name>
    <description>15 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds</description>
    <arm_group_label>Recombinant nonimmunogenic staphylokinase</arm_group_label>
    <other_name>Fortelyzin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>Alteplase® is administered in accordance with the instructions for use for pulmonary embolism ( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.</description>
    <arm_group_label>Alteplase</arm_group_label>
    <other_name>Actillyze</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 18 and over&#xD;
&#xD;
          -  Verified diagnosis of massive PE (using MSCT with PA contrast)&#xD;
&#xD;
          -  Signs of overload / dysfunction of the right ventricle (at least one) in combination&#xD;
             with persistent arterial hypotension or shock&#xD;
&#xD;
          -  Patient consent to use reliable contraceptive methods throughout the study and for 3&#xD;
             weeks after:&#xD;
&#xD;
               -  women who have a negative pregnancy test and use the following contraceptives:&#xD;
                  intrauterine devices, oral contraceptives, contraceptive patch, prolonged&#xD;
                  injectable contraceptives, double barrier method of contraception. Women who are&#xD;
                  not fertile can also take part in the study (documented conditions: hysterectomy,&#xD;
                  tubal ligation, infertility, menopause for more than 1 year);&#xD;
&#xD;
               -  men using barrier contraception. The study may also involve men who are not&#xD;
                  fertile (documented conditions: vasectomy, infertility)&#xD;
&#xD;
          -  Availability of signed and dated informed consent of the patient to participate in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Increased risk of bleeding:&#xD;
&#xD;
               -  Extensive bleeding at present or within the previous 6 months, hemorrhagic&#xD;
                  diathesis;&#xD;
&#xD;
               -  Intracranial (including subarachnoid) hemorrhage at present or in history,&#xD;
                  suspected hemorrhagic stroke;&#xD;
&#xD;
               -  A history of hemorrhagic stroke or stroke of unknown etiology;&#xD;
&#xD;
               -  Ischemic stroke or transient ischemic attack within the last 6 months, except for&#xD;
                  the current acute ischemic stroke within 4.5 hours;&#xD;
&#xD;
               -  A history of diseases of the central nervous system (including neoplasms,&#xD;
                  aneurysms, surgery on the brain or spinal cord);&#xD;
&#xD;
               -  Major surgery or major trauma within the previous 3 months, recent traumatic&#xD;
                  brain injury;&#xD;
&#xD;
               -  Long-term or traumatic cardiopulmonary resuscitation (&gt; 2 min), delivery within&#xD;
                  the previous 10 days, recent puncture of an uncompressible blood vessel (eg,&#xD;
                  subclavian or jugular vein);&#xD;
&#xD;
               -  Severe liver disease, including liver failure, cirrhosis, portal hypertension&#xD;
                  (including esophageal varices) and active hepatitis;&#xD;
&#xD;
               -  Confirmed gastric or duodenal ulcer within the last three months;&#xD;
&#xD;
               -  Neoplasm with an increased risk of bleeding;&#xD;
&#xD;
               -  Concurrent administration of oral anticoagulants, for example, warfarin with an&#xD;
                  INR&gt; 1.3;&#xD;
&#xD;
               -  Arterial aneurysms, developmental defects of arteries / veins;&#xD;
&#xD;
               -  Severe uncontrolled arterial hypertension;&#xD;
&#xD;
               -  Acute pancreatitis;&#xD;
&#xD;
               -  Bacterial endocarditis, pericarditis;&#xD;
&#xD;
               -  suspicion of aortic dissecting aneurysm;&#xD;
&#xD;
               -  any other conditions, in the opinion of the doctor, associated with a high risk&#xD;
                  of bleeding.&#xD;
&#xD;
          -  Lactation, pregnancy&#xD;
&#xD;
          -  Known hypersensitivity to Alteplase, Fortelizin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander I Kirienko, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pirogov Russian National Research Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergey S Markin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Supergene, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sergey S Markin, MD, PhD</last_name>
    <phone>(906) 796-89-06</phone>
    <phone_ext>Ext. +7</phone_ext>
    <email>amsemenof@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Altai Regional Cardiology Dispensary</name>
      <address>
        <city>Barnaul</city>
        <zip>656055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey I Duda, MD</last_name>
      <phone>(3852) 50-89-11</phone>
      <phone_ext>+7</phone_ext>
      <email>alexeyduda@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Alexey I Duda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Krasnodar</city>
        <zip>350012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valery V Makukhin, MD</last_name>
      <phone>(861) 2-220-218</phone>
      <phone_ext>+7</phone_ext>
      <email>makuhinv@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Valery V Makukhin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Kursk</city>
        <zip>305007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pribylov A Sergey, MD,PhD</last_name>
      <phone>(4712) 35-88-08</phone>
      <phone_ext>+7</phone_ext>
      <email>pribylov_serg@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Sergey A Pribylov, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Murmansk Regional Clinical Hospital</name>
      <address>
        <city>Murmansk</city>
        <zip>183047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Garry V Kleyn, MD</last_name>
      <phone>(815) 2-285-177</phone>
      <phone_ext>+7</phone_ext>
      <email>gklein@hotbox.ru</email>
    </contact>
    <investigator>
      <last_name>Garry V Kleyn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Ryazan'</city>
        <zip>390039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis S Yunevich, MD</last_name>
      <phone>(4912) 36-80-40</phone>
      <phone_ext>+7</phone_ext>
      <email>YunevichDen@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Denis S Yunevich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Tver</city>
        <zip>170036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitriy Yu Platonov, MD,PhD</last_name>
      <phone>(4822) 77-54-21</phone>
      <phone_ext>+7</phone_ext>
      <email>diplato64@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Dmitriy Yu Platonov, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital of Emergency №25</name>
      <address>
        <city>Volgograd</city>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduard A Ponomarev, MD,PhD</last_name>
      <phone>(8442) 58-54-13</phone>
      <phone_ext>+7</phone_ext>
      <email>ponomarev67@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Eduard A Ponomarev, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Massive pulmonary embolism</keyword>
  <keyword>Fibrinolysis</keyword>
  <keyword>Recombinant Non-immunogenic Staphylokinase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

